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5 Summary 
 Summary 1
Allergic airway diseases, such as allergic rhinitis (AR) and allergic asthma, are major 
public health problems in Western Europe and industrial countries, and the 
prevalence of these problems has increased dramatically over the past few decades. 
Allergic inflammation arises due to a complex interaction between the immune and 
nervous systems. Bidirectional neuroimmune interactions during allergic inflammation 
has been proposed, and it is believed to play an important role in allergic diseases. 
Communication between immune cells and nerves can occur through either direct 
contact or via soluble mediators and receptors expressed by immune cells and 
nerves. We investigated the interaction of mast cells (MCs) and dendritic cells (DC) 
with nerves in allergic airway diseases in human and mouse models. 
Mast cells (MCs) and nerves play an important role in allergic rhinitis (AR), but little is 
known about their interactions in AR. We found increased crosstalk of MCs with 
nerves in AR by showing the elevated associations between MCs, especially MCs 
expressing tryptase-chymase (MCtc), and nerves fibres. Additionally, the 
neuropeptide receptors NK1R, NK2R and CGRPR were also found to be expressed 
on MCs. The number of MCs expressing NK1R and NK2R but not CGRPR was 
significantly increased in AR. Interestingly, MCtc mostly expressed these 
neuropeptide receptors. Furthermore, tachykinergic nerve fibres were found to 
express PAR2 and TrkA as receptors for MC mediators. These results suggested 
that the interactions of MCs, especially of MCtc with airway nerves, may play an 
essential role in the pathophysiology of allergic rhinitis (Paper I) 
Neuroimmune interactions can occur not only in target organs innervated by nerve 
fibres but also with their neuropeptides and receptors. Immune cells have been 
shown to interact directly with neurons in airway ganglia (Paper II). Immune cells with 
DC-phenotypes were found to be closely located to vagal sensory neurons in the 
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ganglia jugular–nodosum complex (JNC), which innervate the lower airways. The 
number of DC increased significantly in allergic airway inflammation induced by 
house dust mites (HDM). The proliferation analysis suggested that DC migrated into 
the ganglia during allergic airway inflammation. Furthermore, the number of neurons 
expressing Calcitonin Gene-Related Peptide (CGRP), which can induce the migration 
of DCs, was also found to be increased in HDM-treated mice. 
Fluticasone propionate (FP) has been commonly used for treating bronchial asthma 
and chronic obstructive pulmonary disease (COPD). FP treatment was found to 
suppress allergic airway inflammation. However, this treatment did not have any 
effects on the numbers of DCs and neurons expressing CGRP in JNC (Paper III). 
In another study (Paper IV), we investigated the distribution and proliferation of MC 
populations in different lung compartments, along with the association of mast cells 
with nerve endings, using a house dust mite (HDM) model for allergic airway 
inflammation. HDM treatment caused an increased migration of MCs into bronchi, 
alveolar parenchyma and airway vessels. The number of tryptase-chymase 
expressing MC (MCtc) increased significantly in the bronchi and alveolar parenchyma 
but not in the vascular tissues through allergic airway inflammation. Our analysis 
revealed an anatomical connection between MCs and bronchial nerve fibres. Under 
morphological aspects this connection was not changed after HDM treatment.  
Altogether, the data support the hypothesis that mast cell populations may contribute 
to allergic airway inflammation and that the immune-nerve interaction occurred either 
in the affected organs itself and also in the peripheral airway ganglia. Neuro-immune 
interactions may play a crucial role in the pathophysiology of allergic airway 
inflammation, such as allergic rhinitis and allergic asthma. Understanding these 
underlying mechanisms may provide novel therapeutic targets for the treatment of 
allergic disorders. 
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 Zusammenfassung 2
Allergie ist eine Überempfindlichkeitsreaktion des Immunsystems gegen harmlose 
Proteine, auch als Allergene bekannt, wie Pollen, Tierhaare und Hausstaubmilben. 
Allergische Atemwegserkrankungen, wie allergische Rhinitis und allergisches 
Asthma, sind wegen der steigenden Prävalenz in den letzten Jahrzehnten in Europa 
und in Industrieländern zu einer Volkskrankheit geworden. Allergische Entzündung 
kann nach den gegenwärtigen Forschungsergebnissen weder als eine rein 
immunologische noch als eine ausschließlich neurogene Entzündung angesehen 
werden. Bidirektionale neuroimmune Interaktionen wurden erforscht und spielen 
vermutlich eine wichtige Rolle bei allergischen Erkrankungen. Es wurde gezeigt, dass 
neuroimmune Interaktionen über den direkten Kontakt oder über die Mediatoren und 
Rezeptoren der Immunzellen und Nerven vermittelt werden. In den dieser Arbeit 
zugrunde liegenden Studien wurden Interaktionen von Mastzellen und dendritischen 
Zellen mit der Atemwegsinnervation bei allergischen Erkrankungen der Maus und 
Mensch untersucht. 
Mastzellen (MCs) und Atemwegsinnervation spielen eine wichtige Rolle in 
allergischer Rhinitis (AR), jedoch ist über ihre Interaktion noch wenig bekannt. In 
einer Untersuchung wurde erhöhte Kontakte von Nerven mit Mastzellen, inbesondere 
Mastzellen mit Tryptase und Chymase (MCtc) bei AR beobachtet. Zusätzlich wurde 
auch die Expression der Neuropeptidrezeptoren NK1R, NK2R und CGRPR auf MCs  
nachgewiesen. Die Anzahl der Mastzellen, die NK1R und NK2R, aber nicht CGRPR 
exprimieren, war in AR signifikant erhöht. Interessanterweise, exprimierten ein großer 
Teil der MCtc diese Neuropeptidrezeptoren. Umgekehrt konnte gezeigt werden, dass 
tachykinerge Nervenfasern auch Rezeptoren für Mediatoren von MCs wie PAR2 und 
TrkA exprimieren. Diese Ergebnisse deuten daraufhin an, dass die  Interaktion von 
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MCs, insbesondere von MCtc, mit Atemwegsinnervation eine wesentliche Rolle bei 
der Pathophysiologie der allergischen Rhinitis spielen können (Paper I). 
Die neuroimmunen Interaktionen finden nicht nur in den Zielorganen sondern auch in 
den weit entfernten Atemwegsganglien statt. Die Immunzellen können auch direkt mit 
dem Atemwegsneuron in Wechselwirkung treten (Paper II). Es wurde festgestellt, 
dass Immunzellen mit charakteristischen Phänotypen für dendritische Zellen (DCs) 
direkt an vagalsensiblen Neuronen der Atemwegsganglien des Jugular-Nodosum-
Komplex (JNC) lokalisiert sind. Die Anzahl der DCs hat sich bei der Hausstaubmilben 
(HDM)-induzierten allergischen Atemwegsntzündung deutlich erhöht. 
Untersuchungen mittels Proliferationsanalyse  schlossen eine Proliferation der DCs 
in den Ganglien während der allergischen Atemwegsentzündung aus, so dass eine 
Migration von DCs in den Atemwegsganglien bei HDM-behandelten Mäusen 
angenommen wird. 
Fluticasonpropionat (FP) wird häufig für die Therapie von Asthma bronchiale und 
chronisch obstruktive Lungenkrankheit (COPD) verordnet. FP Behandlung 
unterdrückte die HDM induzierte allergische Atemwegsentzündung im Mausmodell, 
hatte jedoch keine Auswirkungen auf die Anzahl von DCs und Neuronen, die CGRP 
in JNC exprimieren (Paper III). 
In weiteren Studien wurden die Verteilung, die Proliferation und das Überleben von 
MC-Populationen in verschiedenen Kompartimenten der Lunge und die Assoziation 
von Mastzellen mit den Nervenfasern in einen HDM-Mausmodell für allergische 
Atemwegsentzündung untersucht. Behandlung mit HDM führte zu einer gesteigerten 
Migration von MCs zu den Bronchien, dem alveolaren Parenchym und 
Atemwegsgefäßen. Die Anzahl der Tryptase-Chymase exprimierten MCs (MCtc) 
erhöhte sich signifikant in den Bronchien und dem Alveolarparenchym, jedoch nicht 
im Bereich um die Gefäße während der allergischen Atemwegsentzündung. Kontakte 
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von MCs und bronchialen Nervenfasern waren zahlreich, vermehrte Kontakte wurden 
bei allergischer Atemwegsentzündung aber nicht gefunden. Die Ergebnisse dieser 
Arbeiten zeigen, dass die Immunzellen, wie die antigenpräsentierenden Zellen DC 
und Mastzellen, direkt mit den Nervenfasern oder indirekt mit den 
Atemwegsneuronen in den Ganglien in Kontakt stehen, so dass neuroimmune 
Interaktionen in den betroffenen Organen und auch in den Atemwegsganglien 
stattfinden können. Ein besseres Verständnis der neuroimmunen Kommunikation 
kann zu einem besseren Verständnis der Pathophysiologie der allergischen 
Atemwegsentzündung führen und somit auch neue therapeutische Möglichkeit 
eröffnen.  
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 Introduction and aims of the studies 3
  Respiratory system 3.1
The cells and tissues within the body require oxygen to stay alive and to function. The 
respiratory system provides oxygenated blood to the body tissues and removes 
carbon dioxide. Anatomically, the respiratory system can be divided into two main 
components: the upper and lower airways [1]. The upper airway extends from the 
sinonasal area to the larynx. Its functions are conducting ambient air directly into the 
trachea, warming, filtering, and humidifying the inspired air and protecting the lower 
airway from foreign materials [2;3]. The lower airway extends from the trachea to the 
lungs. The inspired air is conducted in the lower airway through the many branches 
of the respiratory tree to the alveoli, which are the small air sacs at the end of the 
respiratory bronchioles where gas exchange takes place [4;5]. Continuous exposure 
to airborne allergens, such as pollen and house dust mites may lead to allergic 
diseases of the airways, including allergic rhinitis and allergic asthma [1]. 
  Allergic rhinitis 3.2
Allergic rhinitis is a common inflammatory disease of the nasal mucosa with a high 
prevalence in developed countries. According to World Allergy Organization (WAO), 
over 400 million people of all ages suffer from allergic rhinitis worldwide [6;7]. Allergic 
rhinitis occurs when the immune system mistakenly identifies a typically harmless 
substance, such as pollen, as an intruder [7-10]. Allergic rhinitis can be categorised 
into two types: seasonal allergic rhinitis and perennial allergic rhinitis. Seasonal 
allergic rhinitis is caused by outdoor allergens, such as pollen, while perennial allergic 
rhinitis is caused by indoor allergens, such a pet dander and house dust mites [6-
9;11].  
The typical symptoms of allergic rhinitis, including sneezing, itching and nasal 
congestion, arise as a result of inflammation caused by an IgE-mediated immune 
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response in which the specific allergens bind to the IgE on the surface of basophils 
and mast cells [8-10;12]. This binding leads to the activation of mast cells, which 
results in the release of various mediators, including histamine, proteases, cytokines 
and other compounds. The end result of this mediator release of mast cells is an 
immediate hypersensitivity [8;13-16]. Moreover, mast cell mediators can also induce 
the infiltration of other immune cells as well as activating the nervous system. 
Immune cells and nerves in turn release further inflammatory mediators and 
neuropeptides that can impair the symptoms of allergic rhinitis or can conversely 
affect the functions of mast cells [12;17-20]. 
  Allergic asthma 3.3
Asthma is designated as a serious public health problem that affects approximately 
300 million people of all ages in the world and prevalence has markedly risen in the 
last few decades [21;22]. Allergic bronchial asthma is a chronic inflammatory 
respiratory disease characterised by airway hyperresponsiveness, mucous secretion, 
airflow obstruction and the structural changes in the airways (airway remodelling) [23-
26]. Allergic asthma is triggered by inhaling a harmless substance, such as pollen, 
house dust mites, pet dander or mould. Environmental triggers can concurrently act 
on airway epithelial cells and airway afferent nerves [25;27-29]. The activation of 
epithelial cells initiates the responses of the immune system by releasing cytokines 
and chemokines, which activate or induce the migration, proliferation and 
differentiation of immune cells [23;30]. The activation of airway afferent nerves may 
lead to the release of their own neuropeptides as well as stimulate reflex responses 
that lead to the release of the bronchoconstrictor acetylcholine. The neuropeptides 
can either influence immune cells or contribute to the symptoms of asthma [29;31-35] 
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  Allergy 3.4
Allergic disease is one major public health problem that affects approximately 25% of 
people in Western Europe and industrial countries, and the prevalence increased 
dramatically over the past few decades [36;37]. The term allergy was used for the 
first time in the year 1906 by Clemens von Pirquet in the “Münchener Medizinische 
Wochenschrift” to describe the unusual tendency of some individuals to develop 
signs and symptoms of reactivity when they were exposed to certain substances 
[36;38].  
Allergy is a hypersensitive adaptive immune response to non-infectious 
environmental substances called allergens that are usually harmless, such as house 
dust mite, pollen, and animal dander [25;26;36]. The exaggerated response of the 
immune system may cause damage to the host. Allergy often arises as allergic 
rhinitis, allergic asthma, dermatitis, and anaphylaxis [26;36]. Based on the 
pathophysiological mechanisms, allergy can be divided into four types: type I, type II, 
type III and type IV [39-41].  
Type I or immediate hypersensitivity, is an IgE-mediated allergic reaction. The 
binding of the allergen to the crosslinking of the IgE-Fc-receptor triggers the release 
of histamine and other proinflammatory mediators from mast cells and basophils 
[26;36;40]. These mediators cause a range of allergic symptoms. The reaction 
usually takes several minutes to develop after exposure to the allergen. Examples 
include allergic asthma, allergic rhinitis, allergic conjunctivitis and anaphylaxis [36;39-
41].  
Type II or cytotoxic hypersensitivity reactions are primarily mediated by the 
antibodies of the IgM and IgG classes and their complement. The binding of 
antibodies to antigens on the surface of cells or other tissue components leads to cell 
lysis or extracellular tissue damage via complement activation or antibody-dependent 
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cell-mediated cytotoxicity (ADCC). Examples include transfusion reactions, 
erythroblastosis fetalis, autoimmune haemolytic anaemia and transplant rejection [39-
41]. 
Type III or immune complex reactions are immune complex-mediated allergic 
reactions. Antigen-antibody complexes trigger the complement cascade and 
generate components, including C5a, C3a, C3b. These complement components 
attract polymorphonuclear leukocytes (PMN), which then release lysosomal enzymes 
that lead to inflammatory responses. Antigen-antibody complexes can be deposited 
systemically or locally and cause systemic or local inflammation. Examples include 
systemic lupus erythematosus and serum sickness [39-41].  
Type IV or delayed-type hypersensitivity is a cell-mediated allergic reaction. The 
activation of the CD4+ helper T cells leads to the release of cytokines that activate 
cytotoxic (CD8+) T cells and other immune cells, including macrophages and 
monocytes, which mediate direct cellular and tissue damage. Examples include 
contact dermatitis and granulomatous diseases [39-41]. 
  Pathomechanism of allergy (Type I hypersensitivity) 3.5
Most allergic diseases, including allergic asthma and allergic rhinitis, are type I 
hypersensitivities. The process of allergic inflammation can be divided into two 
stages: sensitization and allergic reactions [40;41] (Figure 1).  
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Figure 1: Mechanisms of type I hypersensitivity. The allergic immune response 
begins with sensitization. Following entry via mucosal surfaces, allergens are taken up by 
local antigen presenting cells, such as dendritic cells. APC then process the allergens and 
they are presented to naïve T-lymphocytes in regional lymph nodes. T cells preferentially 
differentiate to a Th2 phenotype. Cytokines, such as IL4, IL13, and co-stimulatory signals 
from Th2 cells, stimulate B cells to transform memory-activated B cells and antibody 
secreting cells called plasma cells, which produce allergen-specific immunoglobulin E (IgE). 
IgE then sensitizes mast cells and basophils by binding to Fce receptors (FceRs) on their cell 
surfaces. Upon re-exposure, the cross-linking of the IgE–receptor complexes on the surface 
of sensitized mast cells and basophils leads to the degranulation and release of inflammatory 
mediators, including histamine, leukotrienes, and prostaglandins, that cause immediate 
reactions. In late and chronic reactions, the allergens are presented to Th2 by antigen-
presenting cells, such as B cells and dendritic cells. These cells lead to the activation, the 
proliferation and the release of pro-inflammatory cytokines, such as IL-4, IL-5 and IL-13 of 
Th2 cells. Mast cell-derived mediators and Th2 cytokines, such as IL-5, lead to the 
recruitment of eosinophils, which can also release inflammatory mediators. 
 
 Sensitization 3.5.1
The allergic immune response begins with sensitization. When the allergen, such as 
house dust mites, pollen or pet dander, are inhaled, they will be taken up by antigen 
Degranulated
mast cells / basophils
IL
4
, I
L1
3
Plasma cells
Sensitised mast cells / 
basophils
IgE
Sensitisation Re-exposure
Plasma cells
Mucous gland
Smooth musle
Sensory nerve
Eosinophils
Blood vessel
A
lle
rg
y
sy
m
p
to
m
s
H
is
ta
m
in
e
s
Le
u
ko
tr
ie
n
es
C
yt
o
ki
n
e
s
Th2 
A
n
tige
n
 
p
re
se
n
tin
g ce
lls
Th2 
Memory Th2 cells
T cells
B cells
Memory B cells
Dendritic cells
IL
4
, I
L1
3
Late phase reaction, Chronic inflammation
Early-phase reactions
Dendritic cells
 
15 Introduction and aims of the studies 
presenting cells (APC), such as dendritic cells (DC) and macrophages [28;36;40;42]. 
The APC then process the allergens into small antigenic peptides (antigen), which 
are displayed on the cell surface by major histocompatibility complex class II (MHC II) 
molecules and presented to the T cell receptors on the naïve T-lymphocytes in 
regional lymph nodes. That presentation leads to the activation and differentiation of 
CD4+ naïve T-cells to T helper type 2 (Th2) cells [36;40;42;43]. Cytokines, such as 
IL4, IL13, and co-stimulatory signals from Th2 cells, stimulate B cells to transform to 
antibody secreting cells called plasma cells, which produce allergen-specific 
immunoglobulin E (IgE). The secreted IgE antibodies bind through its Fc portion to 
the high affinity receptor FcεRI on the cell surface of various cells, such as mast cells 
and basophils [14;25;36;40]. 
 Allergic reactions 3.5.2
The allergic immune response to allergen by re-exposure can be classified into three 
temporal phases. The early phase reactions occur within seconds to minutes after re-
exposure to the allergen. The late-phase reactions are induced within several hours. 
The chronic allergic inflammation is a constant inflammatory response that occurs if 
the allergen-exposure persists [36;40].  
 Early phase reactions 3.5.2.1
Upon re-exposure, the allergens are captured by mast cell/basophil-bound-IgE 
antibodies. The cross-linking of the FcεRI via IgE-antigen complexes activates the 
intracellular signalling pathways that lead to the degranulation of mast cells or 
basophils with the release of inflammatory mediators, including histamine, 
leukotrienes and prostaglandins. These actions cause a range of allergy symptoms, 
such as oedema caused by the increased vascular permeability and vasodilation, 
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sneezing, airway mucus secretion, bronchoconstriction, urticaria, vomiting and 
diarrhoea [26;28;36;40].  
 Late phase reactions 3.5.2.2
The late phase reactions occur approximately 4 to 6 hours after the allergen 
exposure. The mast cell-derived mediators cause the vascular permeability leading to 
recruitment of leukocytes into the tissue. The mediators, such as IL4 and IL5, act as 
chemoattractants that promote the infiltration and activation of inflammatory cells 
such as Th2 cells, eosinophils, basophils and other leukocytes [24;28;36]. After 
activation, these immune cells release an amount of inflammatory mediators. 
Eosinophils produce and store a variety of mediators, including cytotoxic proteins, 
lipid mediators, and cytokines that lead to epithelial damage. The Th2-lymphocyte-
derived cytokines IL-4 and IL-5 induce IgE production, eosinophil survival and 
inflammatory cell recruitment [28;36]. The late phase response was associated with 
various symptoms, including shortness of breath, coughing, continuous mucus 
production, constant blockage of the nasal passages, swelling and oedema 
[36;39;40].  
 Chronic allergic inflammation 3.5.2.3
Continuous allergen exposure causes persistent inflammation, which is characterized 
by the presence of large numbers of inflammatory cells as well as the alteration of 
structural cells, including goblet cell hyperplasia, airway wall fibrosis, smooth muscle 
thickening and increased vascularity [36;39;40]. 
  Neuroimmune interactions in allergic inflammation 3.6
Allergic inflammation is due to a complex interaction between the immune and 
nervous systems. Bidirectional neuroimmune interplay during allergic inflammation 
has been proposed and is believed to be involved in allergic disorders [32;44]. 
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Previous studies supported this assumption by showing the structural and functional 
associations of immune cells and nerves in several allergic diseases [18;45;46]. The 
communication between immune cells and nerves can occur by either direct contact 
(membrane-to-membrane contact) or via soluble mediators released by immune cells 
and nerves [18;47-49]. The activation of afferent nerves by environmental triggers, 
such as HDM, pollen and pet dander, may lead to a release of neuropeptides and to 
the reflex responses of the autonomic nervous system [29;50]. Neuropeptides, 
including SP and CGRP, can act on either structural cells or immune cells, including 
dendritic cells and mast cells, by inducing the proliferation, migration and mediator 
expression or degranulation that contribute to symptomatic disease [29;31;33]. 
Conversely, immune cell-derived mediators, such as proteases and cytokines, can 
mediate signals from the immune system to the nervous system and stimulate the 
synthesis of neuropeptides, which also contribute to symptoms of allergy [17;51-53]. 
Neuroimmune interactions are believed to play an important role in the 
pathophysiology of allergic diseases and have become a focus of allergy research. 
  Airway innervation 3.7
Airways are richly innervated by autonomic and sensory nerve fibres, which regulate 
many aspects of airway function, including airway and vascular tone, mucus 
secretion, vascular permeability, and the migration and activation of immune cells 
[29;54]. According to traditional classification, the nerve supply of the airways is 
divided into a sensory and autonomic efferent system, including sympathetic and 
parasympathetic innervation [29;32;54;55].  
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 Upper airway innervation 3.7.1
 Sensory innervation of the upper airway 3.7.1.1
The functions of sensory nerves are relaying the signals from organs to the central 
nervous system so that suitable responses in the motor outputs can occur. The 
sensory nerve fibres innervating the nasal mucosa originate from the neurons located 
in the trigeminal ganglion and have been found to innervate blood vessels, glands 
and the epithelium of the nasal mucosa [20;55;56]. Sensory neuropeptides, such as 
tachykinins (substance P (SP)) and CGRP, have also been found in nasal-specific 
trigeminal neurons and nerve fibres projecting to the nasal mucosa [55-57]. Through 
mechanoreceptors and chemosensitive nerve endings, sensory nerve fibres can 
protect the lower respiratory tract against inhaled harmful particles and chemicals 
through nasal protective reflexes [8;20]. Stimuli, such as chemicals, cigarette smoke 
and pollen, can activate sensory neurons and lead to the release of proinflammatory 
neuropeptides, such as SP and CGRP [56;57]. These neuropeptides can induce 
vasodilatation of blood vessels, mucous secretion and the activation of various 
immune cells [20;55-58].  
 Autonomic innervation of upper airway 3.7.1.2
The autonomic nervous system controls the functions of the nose, including nasal 
resistance, the air-conditioning action, mucous secretion, mucus blanket and the 
function of the cilia through sympathetic and parasympathetic nerve fibres. The 
functions of the autonomic nerve systems can become unbalanced during nasal 
inflammation, which may lead to an increase in nasal congestion and nasal 
secretions [20;55;59;60]. Autonomic nerve fibres in the nose originate from the 
superior salivatory nucleus in the brain stem (parasympathetic) and superior cervical 
ganglion (sympathetic) via the pterygopalatine ganglion [55;60].  
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Several sympathetic nerve fibres were found around nasal blood vessels, whereas, 
the parasympathetic nerve fibres abundantly innervate mucus glands [20;55]. 
Stimulation of sympathetic nerve fibres may lead to the release of noradrenaline (NA) 
which causes the contraction of blood vessels in nasal mucosa. Another 
neuropeptide of sympathetic nerve fibres is the neuropeptide tyrosine (NPY). NPY is 
able to regulate the vasoconstriction of the blood vessels [19;55;60]. Nasal 
secretions of mucus glands are controlled by parasympathetic nerve fibres through 
neuropeptides, such as acetylcholine (ACh), whereas other parasympathetic 
neuropeptides, including vasoactive intestinal peptide (VIP), stimulate the 
vasodilatation of blood vessels [12;20;55;60;61].  
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 Lower airway innervation 3.7.2
 
Figure 2: Lower airway innervation. The sensory innervation of the lower airway 
originates from the jugular nodose and dorsal root ganglia. Parasympathetic ganglia located 
within the airway wall are connected with the motor nuclei of the brainstem by vagus nerves. 
Sympathetic neurons, which are derived from the cervical and thoracic spinal cord, are 
located in the cervical and thoracic ganglia, and the sympathetic postganglionic fibres reach 
from these ganglia to the lungs [62-65] 
 
Sensory
Sympathetic
Parasympathetic
Brainstem
Jugular 
Nodose
Ganglia
Complex
(JNC)
Dosal Root Ganglia
Cervical Ganglia
 
21 Introduction and aims of the studies 
 Sensory innervation of the lower airway 3.7.2.1
The largest portion of sensory innervation to the mammalian lungs is carried in the 
vagus nerve. The neuron cell bodies are localised in two distinct vagal sensory 
ganglia, including the nodose ganglion and the jugular ganglion, which provide input 
to the nucleus in the brain stem. These ganglia have also been called the nodose 
and jugular ganglia complex (JNC) in the mouse [35;54;55;63;65-67]. The smaller 
part of sensory nerves innervating the lower airways originates from the dorsal root 
ganglia [68]. Based on the functional properties, the sensory nerve endings were 
categorised in three classes: rapidly adapting stretch receptors (RARs), slowly 
adapting stretch receptors (SARs), and C-fibre endings [32;54].  
Stimuli, such as allergens, cigarette smoke and proinflammatory mediators, can 
activate airway sensory nerves that lead to changes in the motoric outputs and the 
release of neuropeptides, such as tachykinins (SP, NKA) and CGRP, which causes 
various respiratory defence reflexes, such as hyperaemia, oedema, mucus 
hypersecretion, bronchoconstriction, changes in blood pressure and cough 
[29;32;54;63;64;67]. Moreover, sensory neuropeptides can also influence the 
function of various immune cells in the lungs, including dendritic cells [49;69-72] 
(Figure 2).  
 Autonomic innervation of the lower airway 3.7.2.2
Autonomic nervous innervation is derived from the parasympathetic and sympathetic 
nerves to the lower airway and plays a major role in regulating airway smooth muscle 
and vascular tone [29;32;34;54;55;73]. There are two clusters of neuronal cell bodies 
involved in the autonomic nerve pathway. One is located in the brain stem or spinal 
cord and is called a nucleus. It is connected by nerve fibres to the other autonomic 
ganglia [33;54;55;73]. 
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Parasympathetic ganglia located within the airway wall are connected with motor 
nuclei of the brainstem by vagus nerves. The ganglia of the sympathetic nerves are 
located outside the spinal cord, and postganglionic fibres reach from these ganglia to 
the lungs [33;55;73].  
The autonomic innervation in mammalian lower airways is composed mostly of 
parasympathetic nerves terminating in bronchial smooth muscle and submucosal 
glands [33;54;55;73]. Parasympathetic nerves in the human lungs contain 
neurotransmitters, such as acetylcholine (Ach), vasoactive intestinal peptide (VIP) 
and the molecular nitric oxide (NO). Neuropeptides, such as SP and CGRP, were 
also found on airway parasympathetic nerve fibres of other species. Stimulation of 
parasympathetic nerves may lead to the release of Ach that causes 
bronchoconstriction, mucus secretion and bronchial vasodilation [29;31;33;55;73;74].  
Sympathetic nerves were sparsely found around bronchial blood vessels and 
submucosal glands [54;55;73]. The neurotransmitter release by airway sympathetic 
nerves are noradrenalin (NA), neuropeptide Y (NPY), VIP and NO [29;31;54;55;73]. 
Relatively little is known about the functions of airways sympathetic nerves. It could 
be that the sympathetic nervous system regulates the airways via noradrenalin 
receptors (α- and ß-adrenergic receptors), which were found in bronchial smooth 
muscle from the trachea to the terminal bronchioles [31;32;54;75]. Due to the release 
of several neuropeptides, sympathetic nerves may play an important role in the 
physiological and pathophysiological conditions of the airways (Figure 2). 
  Tachykinins 3.8
The tachykinins (also called neurokinins) are a family of closely related 
neuropeptides, which represent one of the largest peptide families described in the 
animal organism [31;76]. The tachykinins are derived from two distinct genes: the 
preprotachykinin-I gene (PPT-I or PPT-A) encodes for substance P (SP), neurokinin 
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A (NKA), neuropeptide K (NPK), and neuropeptide γ (NPγ), while the PPT-II gene (or 
PPT-B) encodes for neurokinin B (NKB). The best known members of the family are 
SP, NKA and NKB [67;76;77]. Tachykinins have been shown to be in a distinct 
subpopulation of primary afferent nerves, which are sensitive to capsaicin. The 
release of tachykinins can be evoked by different stimuli, such as histamine, 
bradykinin, prostaglandins, and leukotrienes [31;76;77].  
The tachykinins are known to have various effects on allergic inflammation 
[35;56;57;76]. SP and NKA have been found to induce the constriction of airway 
smooth muscle, the secretion of the submucosal gland and vascular permeability 
[29;31;33;50;76;77]. Additionally, SP and NKA have the capacity to regulate the 
function and migration of various immune cells, such as mast cells, B cells, T cells, 
eosinophils and neutrophils [78-80]. Tachykinins act on specific membrane receptors 
that belong to the family of G-protein-coupled receptors [76;77]. Three well-
characterised tachykinin receptors are the Neurokinin 1 receptor (NK1R), NK2R, and 
NK3R. All three receptors can be activated by tachykinin Calcitonin Gene-Related 
Peptide (CGRP). However, according to the order of tachykinin potency, three 
receptors are recognized: SP > NKA > NKB for NK1R, NKA > NKB > SP for NK2R 
and NKB > NKA > SP for NK3R [76;77]. Additionally, the newly discovered Mas-
related gene X2 (MrgX2) receptor belongs to a mas-related gene family, which has 
been reported to contain receptors of SP [81-84]. 
  Calcitonin Gene-Related Peptide (CGRP) 3.9
CGRP is a member of the calcitonin family of peptides, consists of 37 amino acids 
and is a product of calcitonin/CGRP pre-mRNA alternative splicing [77;85;86]. CGRP 
is expressed predominantly by the sensory nervous system and is often co-localized 
along with tachykinins [85;87]. This neuropeptide was found to be expressed in nerve 
fibres that project to many organs, including the respiratory system [31;77;86;88]. 
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CGRP acts through the high affinity G-protein coupled receptor called calcitonin 
receptor-like receptor (CRLR) and a receptor activity modifying protein 1 (Ramp1) 
[32;77;87]. 
CGRP is reported to have multiple effects in allergic diseases, such as the regulation 
of bronchoconstriction of airway smooth muscle and vasodilation of vessels 
[29;77;86;87]. Furthermore, CGRP has been described to play an immunomodulatory 
role in the regulation of immune cells, such as dendritic cells and mast cells 
[47;69;70;89]. With respect to its pro-inflammatory role, CGRP has the capacity to act 
as a chemoattractant factor for different immune cells, such as CD4+ T-lymphocytes, 
CD8+ T-lymphocytes, eosinophils and DCs, and it is able to induce the proliferation of 
airway epithelial cells [29;49;69;72;90;91]. On the other hand, CGRP has been 
reported to have anti-inflammatory functions, such as suppression of IL-2 production 
and proliferation in murine T cells and induction of TNF-α secretion in murine bone 
marrow-derived dendritic cells (BMDC) by inhibition of the toll-like receptor (TLR) 
ligand [92-95]. 
 Mast cells 3.10
Mast cells (MCs) are key effector cells in allergic diseases [15;96-98]. When MCs are 
activated, they degranulate and release a number of biologically active molecules 
from their secretory granules. These molecules include histamine, prostaglandins 
(PGs), leukotrienes (LTs), nerve growth factor (NGF) and various MC-specific 
proteases, such as tryptase and chymase [14;16;52;99;100]. These mediators can 
have effects on various cell types, such as immune, epithelium, endothelium and 
airway smooth muscle cells in different compartments of the airway [98;101-103]. 
Based on the type of neutral protease content, human mast cells can be classified in 
two subpopulations, including MCt, which contains only tryptase, and MCtc, which 
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contains chymase in addition to tryptase [98;104;105]. In contrast, rodents have been 
shown to express a number of chymases, such as mast cell protease (mMCP)-1, 
mMCP-2, mMCP-4 and mMCP-5 with distinct proteolytic properties. With respect to 
their biological effects, mMCP-4 expressed by mouse MCs have been suggested to 
be a functional homologue of human chymase [105-108].  
Activation of mast cells can be modulated by various mediators, including 
neuropeptides [109]. Sensory neuropeptides, such as tachykinins (SP and NKA), act 
via neurokinin 1 receptor (NK1R), neurokinin 2 receptor (NK2R) and MrgX2, which is 
a newly discovered receptor belonging to a mas-related gene family (MrgX 
receptors), whereas CGRP activates the CGRP receptor (CGRPR) [16-
18;81;110;111]. Reciprocally, a variety of molecules, including histamine, serotonin 
and nerve growth factor (NGF), which are synthesized and released by mast cells, 
can influence neuronal activity as well as the release of neuropeptides [56;112-114]. 
Additionally, protease-activated receptor 2 (PAR2) and the histamine receptor have 
also been found on trigeminal neurons in animals [115;116]. MCs exhibit variable 
functional aspects of both the nervous and immune systems [18;88;113]. MCs were 
found to be associated with nerve fibres in animal and human tissue under 
physiological and pathophysiological conditions [117-119]. However, little is known 
about the mast cell-nerve interaction in allergic airway inflammation, such as allergic 
rhinitis and allergic asthma .  
 Dendritic cells 3.11
Dendritic cells (DCs) are phagocytic cells that are localised in many organs in the 
skin, in the mucosa of the intestines, the upper airways, the lungs and the brain 
[42;43;120;121]. As professional antigen-presenting cells, DCs play a key role in the 
induction of allergic airway inflammation [42;43;122]. They capture the antigen, 
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process it and subsequently present it to naïve T lymphocytes on the MHC class II 
molecules (MHC II) in local lymph nodes, which leads to the initiation of Th2-immune 
allergic inflammatory processes [43;123;124]. It has been shown that the maturation 
and differentiation of DCs can be modulated by various cytokines as well as 
neuropeptides, such as calcitonin gene-related peptide (CGRP) [69;76;125]. In 
contrast, DCs can activate neurons via secretion of neurotrophins leading to the 
production of neuropeptides that cause neurogenic airway inflammation [126;127]. 
Previously, DCs were found to have a frequent anatomic association with CGRP-
containing sensory nerve fibres of the airways and skin [46;128]. However, DCs in 
airway sensory ganglia have been not explored under normal and allergic airway 
inflammation yet. 
 Aims and Hypotheses 3.12
Paper I: Mast cells (MCs) and trigeminal nerves play an important role in allergic 
rhinitis (AR), but little is known about mast cell-nerve interaction in the nasal mucosa. 
This study aimed to investigate the mast cell-nerve association and neuropeptide 
receptor expression on mast cells in the human nasal mucosa during allergic rhinitis. 
Paper II: Neuroimmune crosstalk between dendritic cells (DCs) and airway nerves in 
the lung has recently been reported. However, the presence of DCs in airway 
sensory ganglia under normal and allergic conditions has not been explored. This 
study therefore aimed to investigate the localisation, distribution and proliferation of 
DCs and CGRP immunoreactive (IR)-neurons in vagal sensory jugular-nodose 
ganglia under allergic airway inflammation by using a chronic house dust mite (HDM) 
mouse model. 
Paper III: DCs were found to be localised in JNC under physiological conditions, and 
their number was significantly increased during allergic airway inflammation by 
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migration from outside the ganglia. However, the impact of fluticasone propionate on 
neuropeptide expression and on the migration of DCs in airway sensory ganglia has 
been not explored so far. The present study aimed to investigate the anti-
inflammatory effects of steroid treatment on the presence and distribution of DCs and 
CGRP immunoreactive neurons in vagal sensory jugular nodose ganglia under 
allergic airway inflammation. 
Paper IV: Mast cells (MCs) and airway nerves play an important role in allergic 
asthma. However, little is known about MCs and their interaction with airway nerves 
during allergic airway inflammation. This study aimed to investigate the distribution 
and proliferation of MC populations in different lung compartments, along with the 
association of mast cell with nerve endings, using a house dust mite (HDM) model for 
allergic airway inflammation. 
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4 Materials and Methods 
  Patients and nasal biopsies 4.1
Fourteen subjects were recruited for this study. Subjects with a positive history of 
allergy symptoms and subjects with a positive prick test for common aeroallergens 
(grass or birch pollen, hazel, Dermatophagoides pteronyssinus, Dermatophagoides 
farinae, cat or dog dander) as well as a positive radioallergosorbent test (RAST test) 
were identified as patients with allergic rhinitis. The allergic rhinitis group contained 
eight patients with perennial allergic rhinitis. All patients had symptoms of allergic 
rhinitis, such as sneezing, itching, nasal blockage, and rhinorrhea at the time of nasal 
surgery. The control group contained six healthy subjects without any allergic 
diseases or symptoms of allergic rhinitis at the time of nasal surgery. All subjects 
were prohibited from taking any anti-inflammatory drugs for at least four weeks prior 
to the nasal surgery. Biopsy specimens of the nasal mucosa were collected from 
2013 to 2014 and taken from the turbinate in nasal surgery to reduce the size of the 
turbinate due to airflow limitations with causes, such as deviation of the septum or 
nasal concha hyperplasia. All specimens were divided into two portions, one for 
cryosections and the other for PCR. All samples were then examined blindly and 
independent of the clinical data. This study was approved by the local ethics 
committee, and all participants provided written consent.  
  Animals 4.2
Female wild-type BALB/c-mice (6-8 weeks old) were purchased from Charles River 
and Janvier-Labs. The animals were held in regular 12 h dark/light cycles at a 
temperature of 22°C and received laboratory food and tap water ad libitum. The 
animals were acclimatised for at least 2 weeks prior to the study. All animal 
experiments were performed in strict concordance with the German animal protection 
law and approved by the appropriate governmental authority. 
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  HDM-mouse models for allergic airway inflammation 4.3
BALB/c mice (n = 10) were exposed for 5 consecutive days per week within a total 
period of 7 weeks by intranasal instillation of HDM extract (Greer Inc., USA) with a 
dose of 25 μg protein in 50 μl of saline. The control group (n = 10) was treated 
intranasally with 50 μl of saline. For the proliferation study animals received an 
intraperitoneal (i.p.) injection of 1 mg of 5-ethynyl-2’-deoxyuridine (EdU) (in DMSO) 
(Invitrogen) at a volume of 200 µl 24 h before sacrifice. Analyses were performed 24 
h after the last allergen challenge (Figure 3).  
 
Figure 3: HDM treatment protocol: The animals were systemically sensitised by 
intranasal application of house dust mites 5 days a week for 7 weeks. 5-ethynyl-2’-
deoxyuridine (EdU) was injected (i.p.) one day before analysis 
 
  Preparation of samples 4.4
After dissection, the human nasal biopsies as well as the mouse samples were 
immediately placed in Zamboni solution (Morphisto – Evolutionsforschung und 
Anwendung GmbH, Frankfurt am Main, Germany). After an overnight fixation, 
specimens were rinsed in 0.1 M phosphate buffered saline (PBS) for 24 hours and 
cryoprotected overnight with 30% sucrose in 0.1 M PBS. All steps in the specimen 
processing were performed at 4°C. The biopsy specimens were embedded in 
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Day  1          8        15        22        29       36        43          48
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optimum cutting temperature (O.C.T) medium (Tissue-Tek, Sakura) and frozen in 
liquid nitrogen. Serial 8-µm sections were prepared using a cryostat (Leica CM 1950, 
Nussloch, Germany), placed on APES (3-aminopropyltriethoxysilane) coated glass 
slides, dried at room temperature for 30 min and then stored in the freezer at -80°C. 
  Preparation of bronchoalveolar lavage fluid (BALF) 4.5
The animals were sacrificed 24 hours following the last airway challenge. Mice were 
anesthetized with an intraperitoneal injection of 0.5 – 0.7 ml/kg of a compound of 
Ketamine (90 - 100 mg /kg bodyweight) and Rompun 6 - 8 mg/kg bodyweight) and 
the tracheae were cannulated with an 18 gauge needle (Dispomed). Bronchoalveolar 
lavage (BAL) was performed by instillation of 1 ml ice-cold PBS containing protease 
inhibitors. The total number of cells was counted using a Casy® cell counter or 
Neubauer chamber. The BALF was centrifuged (320 x g, 10 min, 4°C), and the 
supernatants were removed. The cell pellets were resuspended in 1 ml PBS and 100 
µl of BALF for each mouse were used for the preparation of cytospots with cytospin 
(Tharmacspin). The cytospot-slides were fixed with ice-cold 100% methanol and 
stained with Diff-Quik (Medion Diagnostics), and the differential cell counts were 
evaluated.  
  Histological staining 4.6
Most cells are transparent and colourless. Therefore, the histological stains are 
frequently used to make the cells or structures more visible. The techniques can 
either be a non-specific stain, which stains most of the cells, or a specific stain, which 
stains selectively chemical groupings or molecules of cells or tissues. Staining 
techniques usually work with two steps. First, some components of the cells are 
highlighted by a bright colour by using a dye. The following counterstain stains the 
rest of the cell in a different colour to make the stained structure more easily visible. 
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Acidic dyes colour cationic or basic cell components, including proteins and other 
components in the cytoplasm. Basic dyes stain anionic or acidic cell components, 
such as nucleic acids [129]. 
 Hematoxylin and eosin (H&E) staining 4.6.1
The H&E stain is the most common staining technique used in histology, and it is 
usually used for recognizing various tissue types and morphological changes by 
highlighting the structures and cell populations. H&E stain are combined from two 
dyes, hematoxylin and eosin, to stain different tissue elements. Eosin reacts like an 
acidic dye. Therefore, it stains basic or acidophilic structures, including the cell walls, 
cytoplasm and extracellular fibres in various shades of red, pink and orange. 
Haematoxylin is a basic dye. It colours acidic or basophilic structures, such as the 
cell nucleus and organelles, that contain RNA a purplish blue [129]. 
Procedure 
- Dry cryosections at room temperature for 15 minutes 
- Place in Hematoxylin for 3 min 
- Rinse in running tap water 
- Differentiate with 1 % ethanoic acid for 10 sec 
- Rinse in running tap water 
- Stain with eosin for 1 min 
- Dehydrate in ascending ethanol solutions (70 %, 96 %, 99 %) 
- Clear in xylene for 3 minutes 
- Mount coverslip onto glass slides with Entellan (Merck) 
Results 
Nuclei should be stained blue, and cytoplasm should be stained pink to red (Figure 4) 
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Figure 4: H&E staining of the lungs from mice treated with HDM and saline. 
The lung sections from HDM-sensitised and challenged mice showed infiltration of 
mononuclear cells. Scale bars: 100 µm 
 
 Periodic acid–Schiff (PAS) staining 4.6.2
Periodic Acid–Schiff (PAS) staining is used to detect polysaccharides, including 
glycogen, and mucosubstances, such as glycolipids, glycoproteins and mucins, in 
cells and tissues. 
Procedure 
- Dry cryosections at room temperature for 15 minutes 
- Rehydrate sections in PBS for 5 minutes  
- Oxidize in 0.1% periodic acid solution for 5 minutes 
- Wash in lukewarm tap water for 1 minute 
- Rinse in distilled water for 5 minutes 
- Place in Schiff reagent (Roth) for 20 minutes 
- Rinse in distilled water for 5 minutes 
- Counterstain in hematoxylin (Sigma-Aldrich) for 1 minute 
- Wash in tap water for 5 minutes 
- Dehydrate in ascending ethanol solutions (75%, 80%, 99%) 
SalineHDM
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- Clear in xylene for 3 minutes 
- Mount coverslip onto a labelled glass slide with Entellan (Merck) 
Results 
Glycogen, mucin and some basement membranes should be stained red to purple, 
and the nuclei should be stained blue (Figure 5).  
 
Figure 5: PAS staining of lung tissues from mice treated with HDM and saline. 
C and D are larger magnifications of A and B. The lung sections from HDM-sensitised and 
challenged mice showed more mucus-expressing cells (purple) than saline-treated animals. 
Scale bars: 200 µm in A and B, 50 µm in C and D 
 
 Diff-Quik staining, BALF and NALF differential cell count analysis 4.6.3
Diff-Quick is a modification of the Romanowsky Stain technique, which is used in the 
differential staining of basophilic and acidophilic material. Diff-Quick is a 
polychromatic stain combined from Eosin Y (an anionic dye) and thiazine dyes 
(cationic dyes) that consists of Methylene Blue and Azure A. When applied to 
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immune cells, the dyes produce multiple colours based on the ionic charge of the 
stain and the various cell components. The eosin ions are negatively charged and 
stain the granules in the cytoplasm a bright orange to pink colour. The methylene 
blue ions are positively charged and colour the acid cell component nucleoli and 
cytoplasm in varying shades of blue [130]. In these studies, Diff-Quik staining was 
used to stain the cells in BALF. 
Procedure  
Diff-Quik staining set of Medion Diagnostics was used, and the stain was performed 
according to the manufacturer’s recommendations with modifications as described 
below. 
- Dry slides at room temperature for 15 minutes 
- Dip slides in Stain Solution I for 45 seconds 
- Dip slides in Stain Solution II for 45 seconds 
- Rinse slides in distilled water 
- Mount coverslip onto glass slides with Entellan (Merck) 
 
Results  
Nuclei should be stained dark-blue to blue-violet with blue cytoplasm blue, and 
granules that are red to red-orange (Figure 6).  
 
35 Materials and Methods 
 
Figure 6: Diff-Quik Staining of BALF cells from mice treated with HDM treated: 
M: macrophages, L: lymphocytes, N: neutrophils, E: eosinophils. Scale bars: 50 µm 
 
 BALF and NALF differential cell count analysis 4.6.4
After the Diff-Quick staining, the differential cell counts were evaluated according to 
morphological characteristics of the immune cells using a light microscope. More 
than 300 cells from each sample were counted. 
  Indirect immunofluorescence stain 4.7
Immunofluorescence (IF) is an imaging technique that is based on the use of specific 
antibodies to label a target antigen in cells or tissue sections with a fluorescent dye. 
There are two major types of immunofluorescence stain: direct and indirect 
immunofluorescence. Direct immunofluorescence uses a fluorescent dye-conjugated 
primary antibody to detect the target antigen. Indirect IF uses of an unlabelled 
primary antibody, which binds to the target of interest, and then a fluorescent dye 
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conjugated anti-immunoglobulin antibody (called secondary antibody), which 
recognizes and binds to the constant portion of primary antibody, that indirectly 
localizes the target for detection with a fluorescence microscope. An indirect 
immunofluorescence stain was used in these studies (Figure 7). 
Procedure 
Cryosections were dried at room temperature for 15 minutes and then rehydrated in 
PBS for 5 min. To reduce non-specific antibody binding, the sections were incubated 
for 15 min at room temperature in 5% normal serum of the host species of the 
secondary antibody diluted in 0.1 M PBS. The sections were incubated with primary 
antibodies or the appropriate isotype control antibodies for 1 h at room temperature 
and then overnight at 4°C. After rinsing with 0.1 M PBS twice, the sections were 
incubated with secondary fluorescein-conjugated antibodies for 2 h at room 
temperature. For counterstaining, the sections were incubated with 100 μl of DAPI 
(0.5 μg/ml, Carl Roth, Germany) for 15 min at room temperature. Finally, the sections 
were washed twice with 0.1 M PBS and once with double distilled water, then 
mounted with fluorescent mounting medium Fluoroshield™ (Sigma-Aldrich) or 
Prolong Gold (Invitrogen) and covered with coverslips.  
The slices were visualised with epifluorescence microscopes (Axioskop 2 plus, Axio 
Imager M2 (Carl Zeiss) and Olympus BX5) or a confocal laser scanning microscope, 
LSM 510 META (Carl Zeiss, Jena, Germany). The confocal images were processed 
using Imaris 4.5.2 (Bitplane, Zurich, Switzerland). 
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Figure 7: Principles of an indirect immunofluorescence stain: In the blocking step, 
the IgG in the serum of the host species of the secondary antibody will bind unspecifically to 
the target antigen as well as the non-target antigen. The primary antibody has a high affinity 
to the target antigen and will replace the normal IgG and bind specifically to the epitope on 
the target antigen. The fluorescent dye conjugated secondary antibodies will bind specifically 
to the Fc-portion of the primary antibody. 
 
  In vivo proliferation study with EdU (5-ethynyl-2’-deoxyuridine) 4.8
The Click-iTTM (Invitrogen) method is a technique for labelling DNA in vivo that allows 
researchers to image the replicated DNA in the context of well-preserved cellular and 
chromatin ultrastructure. Click-iTTM reactions using azides and alkynes as specific 
binding moieties in a two-step procedure that first labels and then subsequently 
detects the molecule of interest. In these studies, the 5-ethynyl-2’-deoxyuridine 
(EdU), which contains the alkyne, was used for the labelling step (Figure 8).  
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EdU is a nucleoside analogue of thymidine and is incorporated into DNA during 
active DNA synthesis. Controls and HDM-treated animals received an i.p. injection of 
1 mg of EdU (in DMSO) (Invitrogen) at a volume of 200 µl 24 h before sacrifice.  
Incorporated EdU was detected by using the Click-iTTM Cell reaction buffer kit and 
Alexa Fluor 594 azide (Invitrogen) according to the manufacturer’s protocol. The 
cryosections were rehydrated for 5 min in PBS and then blocked with 5 % normal 
serum. The sections were incubated with 200 µl of the prepared Click-iT reaction 
cocktail for 30 min and then incubated with primary and secondary antibodies as 
described above. 
 
Figure 8: Click-iT technology overview provided by the manufacturer 
(Invitrogen). Click-iTTM reactions use EdU as a specific binding moiety to label replicated 
DNA. Incorporated EdU was detected using an azide tagged with an Alexa FluorTMdye. The 
copper-catalysed click reaction links an alkyne with an azide to form a stable inert product 
(this figure was adapted from Invitrogen materials). 
 
39 Materials and Methods 
  Total RNA extraction, cDNA synthesis and PCR 4.9
  Total RNA extraction 4.9.1
In these studies, total RNA was isolated using an RNeasy Mini Kit (Qiagen, Hilden, 
Germany) according to the manufacturer’s protocol. To remove genomic DNA, 
additional DNase digestion during RNA isolation was performed. The quality of total 
RNA was assessed with a NanoDrop 8000 (Thermo Scientific). 
  cDNA synthesis 4.9.2
Reverse Transcription (cDNA synthesis) was performed using an Omniscript RT kit 
and random primers (Qiagen, Hilden, Germany), according to the following protocol: 
1x cDNA reaction 
10x Buffer RT    2 μl  
dNTP Mix (5 mM each dNTP)   2 μl  
Oligo-dT primer (10 μM)   2 μl  
RNase inhibitor (10 units/μl)  1 μl  
Omniscript Reverse Transcriptase  1 μl 
Total RNA     variable 
H2O      variable 
Total Volume     20 µl 
  Real-time PCR 4.9.3
Real-time PCR was conducted using a CFX96 Touch™ Real-Time PCR Detection 
System (Bio-Rad, Germany) with a SensiMix SYBR & Fluorescein Kit from Bioline 
(Bioline Germany), and the reactions were conducted based on the manufacturer’s 
manual. All samples were run in duplicate and RNA levels were normalized to the 
level of β-actin. The expression of target genes was calculated relative to the control 
group using the ΔΔCt method. Images of the PCR Midori Green Advance-stained 
agarose gels were acquired with the Gel Doc XR+ System (Bio-Rad). 
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AR   Allergic rhinitis 
APC    Antigen-presenting cell 
APES    3-Aminopropyltriethoxysilane 
BALF   Bronchoalveolar lavage fluid 
CGRP   Calcitonin gene-related peptide 
CGRPR  Calcitonin gene-related peptide receptor 
DC    Dendritic cells 
DAPI    4’, 6-diamidino-2-phenylindol dihydrochloride 
EdU    5-ethynyl-2’-deoxyuridine 
FP    Fluticasone propionate 
GFAP   Glial fibrillary acidic protein 
GS    Glutamine synthetase 
HDM    House dust mite 
H&E    Hematoxylin and eosin 
Iba1    Ionized calcium binding adapter molecule 1 
IR    Immunoreactive 
JNC    Jugular-nodose ganglia complex 
LPS    Lipopolysaccharide 
MC   Mast cells 
MCt   Tryptase expressing mast cells 
MCtc   Tryptase and chymase expressing mast cells 
MHC II   Major histocompatibility class II 
NK1R   Neurokinin-1 receptor 
PAS    Periodic Acid Schiff 
PBS    Phosphate buffered saline 
PGP 9.5   Protein gene product 9.5 
SGC    Satellite glia cell 
SP   Substance P 
VIP    Vasoactive intestinal peptide 
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